2024. Cost-per-Responder Analysis of Tralokinumab versus Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis in the US and Canada. SKIN The Journal of Cutaneous Medicine. 8, 1 (Jan. 2024), s317. DOI:https://doi.org/10.25251/skin.8.supp.317.